Primary Bacterial Peritonitis Clinical Trial
Official title:
Is Spontaneous Bacterial Peritonitis Still Responding to 3rd Generation Cephalosporins?
Current European and most other international guidelines recommend the use of a
third-generation cephalosporin as the first choice, or amoxicillin-clavulanate acid or
fluoroquinolones as an alternative choice .
These recommendations are based mainly on clinical trials that were very often conducted a
decade or more ago, and on the assumption that E. coli would be involved in nearly half of
the cases.
The microbial etiology of SBP remains relatively constant; however, the antibiotic
resistance rate especially for third-generation cephalosporins (including cefotaxime and
ceftazidime), ciprofloxacin, and ofloxacin increased dramatically .
Spontaneous bacterial peritonitis (SBP), defined as an infection of ascites in the absence
of a contiguous source of infection.
Spontaneous bacterial peritonitis (SBP) is a common and potentially fatal bacterial
infection in patients with cirrhosis and ascites, occurring in 10 to 30% of patients, with
in-hospital mortality rates ranging from 20 to 30% .
It is secondary to impaired humoral and cellular immune responses that result in indirect
intestinal bacterial translocation into the ascitic fluid .
SBP is also associated with a poor long-term prognosis for patients, as mortality rates can
reach 50 to 70% at 1 year .
Early diagnosis and early optimal treatment of these infections with appropriate antibiotics
and the prevention of hepatorenal syndrome with albumin are required .
Current European and most other international guidelines recommend the use of a
third-generation cephalosporin as the first choice, or amoxicillin-clavulanate acid or
fluoroquinolones as an alternative choice.
These recommendations are based mainly on clinical trials that were very often conducted a
decade or more ago, and on the assumption that E. coli would be involved in nearly half of
the cases.
The microbial etiology of SBP remains relatively constant; however, the antibiotic
resistance rate especially for third-generation cephalosporins (including cefotaxime and
ceftazidime), ciprofloxacin, and ofloxacin increased dramatically.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02463721 -
Identification of Ascitic Fluid Bacterial Pathogens in Spontaneous Bacterial Peritonitis
|
N/A |